Skip to content

Desonide

FDA-approved product (cream, topical), marketed as Desonate, Desonide, Desowen and 1 more.

Registered studies
13
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Desonide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atopic eczema
  • Eye inflammation
  • Skin disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids, moderately potent (group ii); Corticosteroids, plain
FDA pharmacologic class
Corticosteroid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis27.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

13registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Desonide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • URGO FilmoCream Eczema + Dermocorticoids in Atopic Dermatitis

    NCT07295678 · start 2026-01-05

    Registered record
    Registry ID
    NCT07295678
    Conditions
    Atopic Dermatitis
    Interventions
    Treatment period with dermocorticoid alone; Treatment period with combination of URGO FilmoCream Eczema and dermocorticoid; Follow-up period after treatment with URGO Filmocream Eczema associated with dermocorticoid; Follow-up period after dermocorticoid treatment alone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-01-05
    Completion
    2026-12-31
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionTreatment period with dermocorticoid alone; Treatment period with combination of URGO FilmoCream Eczema and dermocorticoid; Follow-up period after treatment with URGO Filmocream Eczema associated with dermocorticoid; Follow-up period after dermocorticoid treatment alone
    PhaseNot applicable
    Registry statusNot yet recruiting
  • Evaluation of the Vasoconstriction Properties of MC2-01 Cream

    NCT03758365 · start 2018-11-05

    Registered record
    Registry ID
    NCT03758365
    Conditions
    Vasoconstriction
    Interventions
    MC2-01 Cream; Clobetasol Propionate 0.05% Lotion; Betamethasone Dipropionate 0.05% Cream; Triamcinolone Acetonide 0.1% Cream; Hydrocortisone Butyrate 0.1% Cream; Desonide 0.05% Cream; Vehicle
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-11-05
    Completion
    2018-11-23
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVasoconstriction
    InterventionMC2-01 Cream; Clobetasol Propionate 0.05% Lotion; Betamethasone Dipropionate 0.05% Cream; Triamcinolone Acetonide 0.1% Cream +3 more
    PhasePhase 1
    Registry statusCompleted
  • 8-Week Atopic Dermatitis (AD) Treatment Study

    NCT03386032 · start 2017-11-27

    Registered record
    Registry ID
    NCT03386032
    Conditions
    Atopic Dermatitis Eczema
    Interventions
    Investigational OTC Cream; 0.05% Desonide; Placebo Cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-11-27
    Completion
    2018-08-18
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis Eczema
    InterventionInvestigational OTC Cream; 0.05% Desonide; Placebo Cream
    PhasePhase 3
    Registry statusCompleted
  • Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis

    NCT02732314 · start 2016-03

    Registered record
    Registry ID
    NCT02732314
    Conditions
    Dermatitis, Atopic; Eczema
    Interventions
    Investigational OTC Cream; Cosmetic Eczema Cream; 0.05% Desonide Cream; Placebo Cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-03
    Completion
    2016-06
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDermatitis, Atopic; Eczema
    InterventionInvestigational OTC Cream; Cosmetic Eczema Cream; 0.05% Desonide Cream; Placebo Cream
    PhasePhase 4
    Registry statusCompleted
  • Proton Pump Inhibitors Use in Patients With Psoriasis

    NCT02624544 · start 2016-01

    Registered record
    Registry ID
    NCT02624544
    Conditions
    Psoriasis
    Interventions
    esomeprazole; desonide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2016-01
    Completion
    2016-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    Interventionesomeprazole; desonide
    PhasePhase 4
    Registry statusWithdrawn
  • Skin Effects of a Topical Amino Acid Moisturizing Cream and Desonide in Atopic Dermatitis

    NCT02286700 · start 2014-11

    Registered record
    Registry ID
    NCT02286700
    Conditions
    Dermatitis, Atopic; Eczema
    Interventions
    Desonide Cream; Amino Acid Moisturizing Cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2014-11
    Completion
    2015-03
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDermatitis, Atopic; Eczema
    InterventionDesonide Cream; Amino Acid Moisturizing Cream
    PhasePhase 3
    Registry statusUnknown
  • Emollients in the Management of Atopic Dermatitis

    NCT01779258 · start 2013-02

    Registered record
    Registry ID
    NCT01779258
    Conditions
    Atopic Dermatitis
    Interventions
    glycerol, paraffin (liquid and white soft); Atopiclair®; Locatop@; Locapred@
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-02
    Completion
    2014-02
    Enrolment
    347

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    Interventionglycerol, paraffin (liquid and white soft); Atopiclair®; Locatop@; Locapred@
    PhasePhase 3
    Registry statusCompleted
  • Alternation in the Human Microbiome With Commonly Used Topical Medications

    NCT03437005 · start 2013-01-28

    Registered record
    Registry ID
    NCT03437005
    Conditions
    Healthy
    Interventions
    Desonide 0.05%; Ketoconazole 2%
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2013-01-28
    Completion
    2026-09-28
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDesonide 0.05%; Ketoconazole 2%
    PhasePhase 1
    Registry statusRecruiting
  • Efficacy Emollient on Xerosis in Children With Atopic Dermatitis

    NCT01467362 · start 2011-11

    Registered record
    Registry ID
    NCT01467362
    Conditions
    Atopic Dermatitis
    Interventions
    V0034CR01B; Vehicle cream; desonide 0.1% cream; Foaming gel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-11
    Completion
    2012-05
    Enrolment
    251

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionV0034CR01B; Vehicle cream; desonide 0.1% cream; Foaming gel
    PhasePhase 3
    Registry statusCompleted
  • Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation

    NCT01542138 · start 2011-07

    Registered record
    Registry ID
    NCT01542138
    Conditions
    Hyperpigmentation
    Interventions
    Desonide; Niacinamide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-07
    Completion
    2012-11
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperpigmentation
    InterventionDesonide; Niacinamide; Placebo
    PhasePhase 4
    Registry statusCompleted
  • Photoaging Treatment With Imiquimod

    NCT01935310 · start 2010-07

    Registered record
    Registry ID
    NCT01935310
    Conditions
    Photoaging
    Interventions
    Imiquimod
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-07
    Completion
    2013-08
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPhotoaging
    InterventionImiquimod
    PhaseNot applicable
    Registry statusCompleted
  • Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis

    NCT00828412 · start 2009-03

    Registered record
    Registry ID
    NCT00828412
    Conditions
    Atopic Dermatitis
    Interventions
    EpiCeram Skin Barrier Emulsion; Desonide Cream 0.05%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-03
    Completion
    2009-08
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionEpiCeram Skin Barrier Emulsion; Desonide Cream 0.05%
    PhasePhase 4
    Registry statusCompleted
  • Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis

    NCT00690833 · start 2007-08

    Registered record
    Registry ID
    NCT00690833
    Conditions
    Atopic Dermatitis
    Interventions
    topical desonide hydrogel 0.05%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-08
    Completion
    2009-11
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    Interventiontopical desonide hydrogel 0.05%
    PhasePhase 4
    Registry statusCompleted